Radionuclide therapy targeting the prostate-membrane specific antigen (PSMA)—a class II membrane glycoprotein frequently overexpressed by prostate cancer cells [2]—with 177Lu-labelled radioligands (PSMA radioligand therapy—PSMA-RLT) is a promising treatment [3,4,5], and its efficacy in the mCRPC-setting has recently been confirmed in the phase III VISION-trial [6]. This evidence concerns the gene FOLH1 and prostate cancer.